As you may be aware, the Department of Health and Human Services has placed a pause on the allocation of REGEN-COV and bamlanivimab/etesevimab based on data indicating they are unlikely to retain activity against the Omicron variant. Kettering Health will not obtain any additional shipments of either COVID-19 monoclonal antibody (mAb) at this time. A request has been placed for sotrovimab, but exact allocation and arrival time is currently unknown.
To conserve inventory, the Kettering Health Pharmacy and Therapeutics Committee has approved changes to the COVID-19 monoclonal antibody (mAb) restrictions for both hospital and infusion center use:
- Restricted to treatment only. Kettering Health will no longer utilize monoclonal antibody for post-exposure prophylaxis (PEP).
Changes to EPIC referral forms and order panels will be forthcoming.
Please consider the following when prescribing COVID-19 mAbs:
- We estimate a 7-day supply on hand based on current inventory and usage.
- Due to a high volume of referral orders, there is a 3-day lag time for treatment at the COVID Infusion Center
- Practitioners should counsel patients on the lack of efficacy of these agents against the Omicron variant
Please see the order form for complete list of requirements for COVID-19 monoclonal antibody use.
We will continue to reevaluate this decision at regular intervals and provide updates to these restrictions as appropriate.